- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01956500
Instaflex and Joint Pain in Community Adults
Influence of Instaflex Joint Support Supplement on Joint Pain, Stiffness, Function, and Inflammation: a Randomized, Placebo-controlled Community Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Allocation: Randomized. Subjects will be randomized to one of two groups: placebo or Instaflex Joint Support. Supplements will be administered in double-blinded fashion.
Intervention Model: Instaflex Joint Support supplement for 8 weeks versus placebo.
Sample Size: N=100, with N=50 per group.
Statistical Procedures: 2 x 2 repeated measures analysis of variance (ANOVA).
Study Duration (per subject): 8 weeks.
Blood sample schedule: Blood draws pre- and post-study.
Monitoring adverse events: Subjects will fill in bi-weekly symptom logs to monitor untoward symptoms. Diagnostic chemistry panels will be measured pre- and post-study.
Rescue medication: Paracetamol (i.e., acetaminophen as found in Tylenol) will be allowed as a rescue medicine for pain during the study as needed. Subjects will record paracetamol usage. Paracetamol can relieve pain in mild arthritis but has no effect on the underlying inflammation, redness, and swelling of the joint.
Lab visit testing sequence (at the Kannapolis YMCA, in the afternoon by appointment.):
First visit:
- Consent form
- Medical health questionnaire to verify medical history, and lifestyle habits.
- Symptoms log for previous 2-weeks symptomatology
- Height, weight, and percent body fat (bioelectrical impedance, Tanita scale)
- Questionnaires: Western Ontario and McMaster Universities Arthritis Index (WOMAC), Short Form (36) Health Survey (SF-36), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP).
- Blood sample (followed by a glass of orange juice)
- 6-minute walk test (at the local YMCA track) (one practice trial, and then repeat for test).
- Receive supplement organizer tray with 8-weeks supply (and instructions)
8-week study:
a. Subjects will be contacted via email every 2 weeks to monitor compliance and fill in symptom logs.
Second lab visit:
- Same as first lab visit, except for removal of steps "a,b, and h".
Supplements:
Supplements (Instaflex, placebo) will be prepared in colored gel capsules (3 per day, identical looking), and given to the subjects in supplement organizer trays. Subjects will take 3 capsules/day: one capsule each in the morning, at noontime, and in the evening. The placebo capsules will contain magnesium stearate, an inert substance.
Compliance:
Compliance will be monitored with bi-weekly email messages, and by counting unused capsules when subjects return the supplement trays at the end of the 8-week study. If subjects miss one, two, or three days of taking supplements, subjects will be asked to double up usage until back on schedule. Subjects missing more than three days of taking the supplements will be asked to leave the study.
1. Instaflex Joint Support Supplement
A serving size is 3 capsules, and contains the following ingredients:
Glucosamine Sulfate 1500 mg Methylsulfonylmethane 500 mg White Willow Bark Extract (standardized to 15% salicin) 250 mg Ginger Root Concentrate 50 mg Boswella Serrata Extract (Standardized to 65% boswellic acid) 125 mg Turmeric Root Extract 50 mg Cayenne 40m H.U. 50 mg Hyaluronic Acid 4.0 mg Other Ingredients: Rice Flour, Gelatin, Vegetable Magnesium Stearate, Silicon Dioxide
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Kannapolis, North Carolina, United States, 28081
- ASU Human Performance Laboratory, North Carolina Research Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- ages 50-75 years
- history (>3 months) joint pain, knees, hip, ankles, shoulders, or hands
- willingness to avoid NSAIDs use during the 8-week study
- willingness to avoid other anti-inflammatory medications
- agree to stay weight stable during the 8-week study
- willing to follow all study procedures, including randomization to one of two groups
- able to walk for at least 6 min at a moderate-to-brisk pace
Exclusion Criteria:
- history of regular NSAID use during the previous two weeks
- use of other medications (e.g., analgesic gels, arthritis medications, other anti-inflammatory drugs) or supplements (in particular, glucosamine and chondroitin) for joint pain for the previous two weeks
- serious medical problems (current cancer case, severe rheumatoid arthritis, recent heart attack, recent stroke, congestive heart failure, ulcers, kidney disease, or other disease that will interfere with study participation).
- psychiatric disorder or other condition that might interfere with self-assessment ability.
- history of allergic reactions to shellfish products.
- history of allergic reactions to products containing aspirin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Instaflex
Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
|
The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
Other Names:
|
Placebo Comparator: Placebo
Placebo (3 capsules per day for 8 weeks)
|
The placebo capsules will contain magnesium stearate, an inert substance.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Joint pain and function
Time Frame: Change in joint pain and function at 8 weeks
|
Assessed through questionnaires
|
Change in joint pain and function at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systemic inflammation
Time Frame: Change in systemic inflammation at 8 weeks
|
Serum CRP and plasma cytokines (9 total)
|
Change in systemic inflammation at 8 weeks
|
Safety
Time Frame: Change in safety outcomes at 8 weeks
|
Symptoms logs and diagnostic chemistries
|
Change in safety outcomes at 8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David C. Nieman, DrPH, Appalachian State University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-0173
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Joint Pain, Stiffness, Function
-
St George's, University of LondonUnknownEndothelial Function and Arterial StiffnessUnited Kingdom
-
Ball State UniversityCompletedAging | Endothelial Dysfunction | Arterial Stiffness | Cardiovascular FunctionUnited States
-
ESM Technologies, LLCQPS Bio-Kinetic; KD Pharma GroupCompletedExercise-induced Joint Pain | Exercise-induced Joint Stiffness | Exercise-induced Joint Cartilage TurnoverUnited States
-
ESM Technologies, LLCQPS Bio-KineticCompletedExercise-induced Joint Pain | Exercise-induced Joint Stiffness | Exercise-induced Joint Cartilage TurnoverUnited States
-
ESM Technologies, LLCQPS Bio-KineticCompletedExercise-induced Joint Pain | Exercise-induced Joint Stiffness | Exercise-induced Joint Cartilage TurnoverUnited States
-
ESM Technologies, LLCCompletedExercise-induced Joint Pain Stiffness and Cartilage Turnover
-
Uriach Consumer HealthcareQuironsaludCompletedJoint Pain | Musculoskeletal Pain | Chronic Pain | Stiffness of Unspecified Joint, Not Elsewhere ClassifiedSpain
-
University of Massachusetts, AmherstRecruitingArthralgia | Joint Stiffness | Gait MechanicsUnited States
-
Brigham and Women's HospitalUnknown
-
University of Castilla-La ManchaRecruitingHeart Failure | Exercise Capacity | Diastolic Function | Endothelial Function | Arterial Stiffness | Physical ExerciseSpain
Clinical Trials on Instaflex
-
Appalachian State UniversityDirect DigitalCompleted